NYX Nyse Euronext

NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for February 20131. Global derivatives average daily volume (“ADV”) of 8.8 million contracts in February 2013 increased 24.7% compared to February 2012, but decreased 7.6% month-over-month. This increase was primarily driven by stronger European derivatives volume, specifically fixed income derivatives ADV which increased 71% year-over-year. U.S. equity options ADV increased 5.7% compared to February 2012, but decreased 9.8% from January 2013 levels. Trading volumes in European cash equities were down 9.8% year-over-year, but rebounded up 12.8% month-over-month.

Highlights

• NYSE Euronext global derivatives ADV in February 2013 of 8.8 million contracts increased 24.7% compared to February 2012, but decreased 7.6% from January 2013 levels.
• NYSE Euronext European derivatives products ADV in February 2013 of 4.4 million contracts increased 54.4% compared to February 2012, but decreased 10.0% from January 2013 levels. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV increased 45.7% compared to February 2012, but decreased by 5.2% from January 2013.
• NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex) ADV of 4.3 million contracts in February 2013 increased 5.7% compared to February 2012 levels but decreased by 5.2% from January 2013 levels. NYSE Euronext’s U.S. options exchanges accounted for 28.2% of total U.S. consolidated equity options trading in February 2013.
• NYSE Euronext European cash products ADV of 1.5 million transactions in February 2013 decreased 9.8% compared to February 2012, but increased 12.8% compared to January 2013.
• NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.6 billion shares in February 2013 decreased 11.9% compared to February 2012 but increased 0.6% compared to January 2013. NYSE Euronext’s Tape A matched market share in February 2013 was 29.4%, down from 30.0% in February 2012 and down from 29.7% in January 2013.

Please click here for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

This communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other “forward-looking” information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.

Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE and NYSE Euronext, including future financial results, ICE’s and NYSE Euronext’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE’s and NYSE Euronext’s filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the inability to complete the merger due to the failure of NYSE Euronext stockholders to adopt the merger agreement or the failure of ICE stockholders to approve the issuance of ICE common stock in connection with the merger; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext’s operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE’s, NYSE Euronext’s or the combined company’s respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management’s attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled “Risk Factors” in the joint proxy statement/prospectus filed by ICE with the SEC, and as described in ICE’s and NYSE Euronext’s respective filings with the SEC that are available on the SEC’s web site located at www.sec.gov, including the sections entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and “Risk Factors” in NYSE Euronext’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, neither ICE nor NYSE Euronext undertakes any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.

IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE has filed with the SEC a registration statement on Form S-4, which includes a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext. The final joint proxy statement/prospectus will be delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC’s website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE’s website at http://www.theice.com and from NYSE Euronext’s website at http://www.nyx.com

PARTICIPANTS IN THE MERGER SOLICITATION

ICE, NYSE Euronext and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the Merger Agreement.

You can find information about ICE and ICE’s directors and executive officers in ICE’s Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 6, 2013, and ICE’s proxy statement for its 2012 annual meeting of stockholders, as filed with the SEC on March 30, 2012.

You can find information about NYSE Euronext and NYSE Euronext’s directors and executive officers in NYSE Euronext’s Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 26, 2013, and NYSE Euronext’s proxy statement for its 2012 annual meeting of stockholders, filed with the SEC on March 26, 2012.

Additional information about the interests of potential participants will be included in the joint proxy statement/prospectuses, when it becomes available, and the other relevant documents filed by ICE and NYSE Euronext with the SEC.

1 All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

                                                 

NYSE Euronext

Monthly Volume Summary

   

Average Daily Volume

Total Volume

Average Daily Volume

Total Volume

(Unaudited; contracts in thousands) Feb-13 Feb-12 % Chg Feb-13 Feb-12 % Chg YTD 2013

% Chg vs.YTD 2012

YTD 2013

% Chg vs.YTD 2012

  Number of Trading Days - European Cash 20 21 20 21 42 42 Number of Trading Days - European Derivatives 20 21 20 21 42 42 Number of Trading Days - U.S. Markets 19 20 19 20 40 40   European Derivatives Products 4,383 2,839 54.4% 87,653 59,624 47.0% 4,636 52.8% 194,730 49.2% of which Bclear 667 342 95.0% 14,861 7,181 107.0% 983 12.7% 37,465 95.2%   Total Fixed Income Products 2,736 1,596 71.4% 54,716 33,526 63.2% 2,889 67.7% 121,318 63.8%   Short Term Interest Rate Products 2,487 1,398 77.9% 49,742 29,364 69.4% 2,681 71.4% 112,615 67.4% Medium and Long Term Interest Rate Products 1 249 198 25.5% 4,974 4,162 19.5% 207 31.3% 8,703 28.2%   Total Equity Products 2 1,549 1,155 34.1% 30,980 24,262 27.7% 1,655 34.3% 69,498 31.2%   Individual Equity Products 1,026 745 37.7% 20,526 15,652 31.1% 1,152 39.2% 48,372 35.9% Futures 577 214 169.2% 11,531 4,497 156.4% 689 122.3% 28,953 117.1% Options 450 531 -15.3% 8,995 11,155 -19.4% 462 -10.7% 19,419 -12.7% Equity Index Products 523 410 27.5% 10,453 8,610 21.4% 503 24.4% 21,126 21.5%   of which Bclear 657 342 92.0% 14,788 7,181 105.9% 981 12.4% 37,367 94.7% Individual Equity Products 555 293 89.3% 12,745 6,153 107.1% 865 12.9% 32,492 92.8% Futures 555 190 192.2% 11,090 3,986 178.2% 673 15.5% 28,273 120.5% Options - 103 1,654 2,167 -23.7% 192 4.7% 4,220 4.7% Equity Index Products 102 49 108.7% 2,043 1,028 98.8% 116 9.1% 4,875 108.3%   Commodity Products 98 87 11.9% 1,958 1,836 6.6% 93 14.9% 3,914 12.2%   U.S. Derivatives Products   Equity Options 3   NYSE Euronext Options Contracts 4,346 4,110 5.7% 82,574 82,197 0.5% 4,471 8.0% 178,837 8.0% Total Consolidated Options Contracts 15,399 16,165 -4.7% 292,573 323,293 -9.5% 15,496 -2.6% 619,838 -2.6%   NYSE Group Share of Total 28.2% 25.4% 28.2% 25.4% 28.9% 2.9% 28.9% 2.9%   NYSE Liffe U.S.   Futures and Futures Options Volume* 48.0 88.6 -45.8% 960 1,861 -48.4% 49.5 -46.0% 2,080.0 -46.0%   European Cash Products (trades in thousands) 1,458 1,617 -9.8% 29,163 33,961 -14.1% 1,371 -12.2% 57,599 -14.3%   Equities 1,403 1,564 -10.3% 28,063 32,854 -14.6% 1,319 -12.6% 55,391 -14.6% Exchange-Traded Funds 15 13 9.0% 294 283 3.8% 14 -5.2% 578 -7.4% Structured Products 35 34 1.0% 696 723 -3.8% 33 -4.9% 1,378 -7.1%

Bonds

5 5 14.8% 110 100 9.3% 6 28.3% 252 25.3%   U.S. Cash Products (shares in millions) 5 1,563 1,774 -11.9% 29,689 35,488 -16.3% 1,558 -13.2% 62,314 -13.2%   NYSE Listed (Tape A) Issues 4   Handled Volume 5 1,123 1,259 -10.8% 21,335 25,181 -15.3% 1,122 -12.0% 44,889 -12.0% Matched Volume 6 1,078 1,185 -9.1% 20,477 23,702 -13.6% 1,077 -10.4% 43,071 -10.4% Total NYSE Listed Consolidated Volume 3,670 3,950 -7.1% 69,725 79,010 -11.8% 3,645 -8.5% 145,781 -8.5%   Share of Total Consolidated Volume Handled Volume 5 30.6% 31.9% -1.3% 30.6% 31.9% -1.3% 30.8% -1.2% 30.8% -1.2% Matched Volume 6 29.4% 30.0% -0.6% 29.4% 30.0% -0.6% 29.5% -0.6% 29.5% -0.6%   NYSE Arca, MKT and Regional (Tape B) Listed Issues   Handled Volume 5 230 258 -10.7% 4,379 5,162 -15.2% 224 -15.6% 8,944 -15.6% Matched Volume 6 213 231 -7.4% 4,055 4,610 -12.0% 206 -12.8% 8,249 -12.8% Total NYSE Arca & MKT Listed Consolidated Volume 1,035 1,127 -8.1% 19,670 22,532 -12.7% 991 -11.5% 39,647 -11.5%   Share of Total Consolidated Volume Handled Volume 5 22.3% 22.9% -0.6% 22.3% 22.9% -0.6% 22.6% -1.0% 22.6% -1.0% Matched Volume 6 20.6% 20.5% 0.1% 20.6% 20.5% 0.1% 20.8% -0.3% 20.8% -0.3%   Nasdaq Listed (Tape C) Issues   Handled Volume 5 209 257 -18.7% 3,976 5,145 -22.7% 212 -16.5% 8,482 -16.5% Matched Volume 6 187 217 -13.7% 3,554 4,335 -18.0% 189 -12.3% 7,554 -12.3% Total Nasdaq Listed Consolidated Volume 1,892 1,901 -0.5% 35,955 38,024 -5.4% 1,883 1.3% 75,312 1.3%   Share of Total Consolidated Volume Handled Volume 5 11.1% 13.5% -2.4% 11.1% 13.5% -2.4% 11.3% -2.4% 11.3% -2.4% Matched Volume 6 9.9% 11.4% -1.5% 9.9% 11.4% -1.5% 10.0% -1.6% 10.0% -1.6%   Exchange-Traded Products 5,7   Handled Volume 5 220 240 -8.0% 4,186 4,792 -12.6% 214 -13.8% 8,541 -13.8% Matched Volume 6 204 214 -4.3% 3,882 4,272 -9.1% 197 -10.7% 7,882 -10.7% Total ETF Consolidated Volume 1,007 1,085 -7.2% 19,133 21,693 -11.8% 961 -10.9% 38,447 -10.9%   Share of Total Consolidated Volume Handled Volume 5 21.9% 22.1% -0.2% 21.9% 22.1% -0.2% 22.2% -0.7% 22.2% -0.7% Matched Volume 6 20.3% 19.7% 0.6% 20.3% 19.7% 0.6% 20.5% 0.0% 20.5% 0.0%

 

1   Data includes currency products. 2

Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives.

3 Includes trading in U.S. equity options contracts, not equity-index options. 4 Includes all volume executed in NYSE Group crossing sessions. 5 Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots. 6 Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges. 7 Data included in previously identified categories. * ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days. Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities. All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.    

Please follow us at:Exchanges BlogFacebookLinkedInTwitter